I received a telephone call recently from a man who was angry and upset. All he could say was, but I’m not dying, I’m not dying! I was finally able to calm him down enough to be able to get him to tell me his story. It seems that his doctor told him that it [...]
As of today there are many different potential drugs undergoing phase III evaluations for men with advanced prostate cancer, some of them seem to offer great hope and promise. Considering we just had Provenge finally approved, this is great news. […]
A phase III study released at the ASCO meeting demonstrated that for men with bone metastases from prostate cancer, denosumab was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. […]
We have talked about it many times in past posts, the potential that many believe combination therapy can hold for better treatments for all cancers, including advanced prostate cancer. Combination therapy has made AIDS treatment as successful as it has become and it holds a similar promise for cancer treatment. An example of this potential [...]
In 2007 a Norwegian cancer therapeutics company, Algeta, presented data from a phase II study that showed a remarkable two-year survival advantage with its investigational drug, Alpharadin (radium-223), when used as a as a treatment for castrate resistant prostate cancer (CRPC). […]
At the on-going AUA Meeting, Dr. Howard Scher along with a collaborating group of medical oncologists reported their data from a Phase I-II trial of MDV3100 in castration-resistant prostate cancer (CRPC). […]
The National Comprehensive Cancer Network (NCCN), a private organization which develops what has become the standard of care guidelines for clinical practice in oncology, has modified their guidelines to included sipuleucel-T (Provenge) as a part of its prostate cancer management guidelines. The guidelines specify Provenge as a category 1 treatment which is appropriate as salvage [...]
According to a study last year at Fox Chase Cancer Center, men whose prostate specific antigen (PSA) rise within 18 months of having primary radiotherapy are more likely to develop advanced prostate cancer and die of their disease. […]
It has been clearly shown that androgen deprivation therapy (ADT) for the treatment of prostate cancer leads to loss of bone mineral density (BMD) and increased fracture risk. More importantly, loss of BMD shortens survival time. (see my post of December 27, 2009 “On the Horizon – Dasatinib A Drug to Inhibit the growth of [...]
Docetaxel is the first-line chemotherapy and the only approved chemotherapy for men with metastatic castrate resistant prostate cancer (CRPC). We all know that Docetaxel will stop working, so what do you do when this happens? […]
